Renovaro (RENB) Competitors $0.32 -0.04 (-10.48%) As of 12:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RENB vs. ITOS, CMPX, AVIR, TERN, ACB, SLDB, ATXS, SLRN, CDTX, and HUMAShould you be buying Renovaro stock or one of its competitors? The main competitors of Renovaro include iTeos Therapeutics (ITOS), Compass Therapeutics (CMPX), Atea Pharmaceuticals (AVIR), Terns Pharmaceuticals (TERN), Aurora Cannabis (ACB), Solid Biosciences (SLDB), Astria Therapeutics (ATXS), Acelyrin (SLRN), Cidara Therapeutics (CDTX), and Humacyte (HUMA). These companies are all part of the "pharmaceutical products" industry. Renovaro vs. iTeos Therapeutics Compass Therapeutics Atea Pharmaceuticals Terns Pharmaceuticals Aurora Cannabis Solid Biosciences Astria Therapeutics Acelyrin Cidara Therapeutics Humacyte Renovaro (NASDAQ:RENB) and iTeos Therapeutics (NASDAQ:ITOS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, community ranking, dividends and earnings. Do insiders & institutionals believe in RENB or ITOS? 71.4% of Renovaro shares are owned by institutional investors. Comparatively, 97.2% of iTeos Therapeutics shares are owned by institutional investors. 21.7% of Renovaro shares are owned by insiders. Comparatively, 12.5% of iTeos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has stronger valuation & earnings, RENB or ITOS? Renovaro has higher earnings, but lower revenue than iTeos Therapeutics. iTeos Therapeutics is trading at a lower price-to-earnings ratio than Renovaro, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRenovaroN/AN/A-$80.65M-$0.93-0.35iTeos Therapeutics$35M8.09-$112.64M-$3.31-2.24 Does the MarketBeat Community prefer RENB or ITOS? iTeos Therapeutics received 47 more outperform votes than Renovaro when rated by MarketBeat users. CompanyUnderperformOutperformRenovaroN/AN/AiTeos TherapeuticsOutperform Votes4781.03% Underperform Votes1118.97% Do analysts prefer RENB or ITOS? iTeos Therapeutics has a consensus target price of $25.50, indicating a potential upside of 244.18%. Given iTeos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe iTeos Therapeutics is more favorable than Renovaro.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Renovaro 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00iTeos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to RENB or ITOS? In the previous week, iTeos Therapeutics had 8 more articles in the media than Renovaro. MarketBeat recorded 10 mentions for iTeos Therapeutics and 2 mentions for Renovaro. Renovaro's average media sentiment score of 1.21 beat iTeos Therapeutics' score of 0.74 indicating that Renovaro is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Renovaro 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iTeos Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is RENB or ITOS more profitable? iTeos Therapeutics' return on equity of -20.11% beat Renovaro's return on equity.Company Net Margins Return on Equity Return on Assets RenovaroN/A -61.84% -48.07% iTeos Therapeutics N/A -20.11%-17.50% Which has more risk & volatility, RENB or ITOS? Renovaro has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500. SummaryiTeos Therapeutics beats Renovaro on 10 of the 15 factors compared between the two stocks. Get Renovaro News Delivered to You Automatically Sign up to receive the latest news and ratings for RENB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RENB vs. The Competition Export to ExcelMetricRenovaroPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$51.74M$6.79B$5.53B$7.99BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-0.357.4422.6518.64Price / SalesN/A244.75401.98103.80Price / CashN/A65.8538.1834.62Price / Book0.636.536.754.30Net Income-$80.65M$143.43M$3.22B$248.44M7 Day Performance-12.55%2.23%1.66%1.81%1 Month Performance-34.88%7.19%4.17%4.40%1 Year Performance-77.82%-2.24%16.17%5.97% Renovaro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RENBRenovaro1.3815 of 5 stars$0.32-10.5%N/A-77.2%$50.95MN/A-0.3520Positive NewsITOSiTeos Therapeutics2.0936 of 5 stars$6.62+1.7%$25.75+289.0%-32.5%$252.84M$35M-2.1090Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageCMPXCompass Therapeutics3.3905 of 5 stars$1.78+1.7%$13.38+651.4%+29.2%$246.14M$850,000.00-4.8120Analyst ForecastShort Interest ↑Analyst RevisionAVIRAtea Pharmaceuticals3.1648 of 5 stars$2.86-3.7%$6.00+109.8%-20.3%$244.60MN/A-1.3870Positive NewsTERNTerns Pharmaceuticals4.2798 of 5 stars$2.71+12.9%$18.38+578.0%-34.7%$236.58MN/A-2.3040Positive NewsACBAurora Cannabis0.6363 of 5 stars$4.20-5.4%N/A-49.7%$236.10M$320.81M84.021,340News CoverageSLDBSolid Biosciences3.9803 of 5 stars$3.03+18.8%$15.67+417.1%-62.7%$234.80M$8.09M-1.00100High Trading VolumeATXSAstria Therapeutics2.5439 of 5 stars$4.11+1.7%$26.60+547.2%-43.8%$231.94MN/A-1.9730Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageSLRNAcelyrin2.9976 of 5 stars$2.28+3.6%$9.60+321.1%-40.9%$230.07MN/A-0.93135Positive NewsCDTXCidara Therapeutics4.2432 of 5 stars$20.68+6.4%$39.14+89.3%+74.4%$226.51M$1.28M-0.8190Analyst ForecastNews CoveragePositive NewsHUMAHumacyte2.807 of 5 stars$1.45-13.7%$13.71+845.8%-63.0%$224.92M$1.57M-1.08150News Coverage Related Companies and Tools Related Companies iTeos Therapeutics Alternatives Compass Therapeutics Alternatives Atea Pharmaceuticals Alternatives Terns Pharmaceuticals Alternatives Aurora Cannabis Alternatives Solid Biosciences Alternatives Astria Therapeutics Alternatives Acelyrin Alternatives Cidara Therapeutics Alternatives Humacyte Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RENB) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renovaro Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Renovaro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RENB Stock Free RENB Stock Alerts